Equity Overview
Price & Market Data
Price: $4.15
Daily Change: +$0.02 / 0.48%
Daily Range: $4.13 - $4.17
Market Cap: $504,046,048
Daily Volume: 14,736
Performance Metrics
1 Week: 2.23%
1 Month: -2.13%
3 Months: -33.71%
6 Months: -28.79%
1 Year: 57.63%
YTD: -36.07%
Company Details
Employees: 147
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.